PLUS THERAPEUTICS INC (PSTV) Fundamental Analysis & Valuation
NASDAQ:PSTV • US72941H5090
Current stock price
0.2393 USD
+0 (+1.4%)
Last:
This PSTV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PSTV Profitability Analysis
1.1 Basic Checks
- PSTV had negative earnings in the past year.
- PSTV had a negative operating cash flow in the past year.
- PSTV had negative earnings in each of the past 5 years.
- In the past 5 years PSTV always reported negative operating cash flow.
1.2 Ratios
- PSTV has a worse Return On Assets (-110.19%) than 78.76% of its industry peers.
- PSTV's Return On Equity of -407.06% is on the low side compared to the rest of the industry. PSTV is outperformed by 75.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -110.19% | ||
| ROE | -407.06% | ||
| ROIC | N/A |
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PSTV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. PSTV Health Analysis
2.1 Basic Checks
- PSTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
- PSTV has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, PSTV has more shares outstanding
- PSTV has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -38.18, we must say that PSTV is in the distress zone and has some risk of bankruptcy.
- PSTV has a worse Altman-Z score (-38.18) than 90.54% of its industry peers.
- PSTV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -38.18 |
ROIC/WACCN/A
WACC8.21%
2.3 Liquidity
- A Current Ratio of 1.29 indicates that PSTV should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.29, PSTV is doing worse than 83.59% of the companies in the same industry.
- PSTV has a Quick Ratio of 1.29. This is a normal value and indicates that PSTV is financially healthy and should not expect problems in meeting its short term obligations.
- PSTV's Quick ratio of 1.29 is on the low side compared to the rest of the industry. PSTV is outperformed by 83.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. PSTV Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 32.54% over the past year.
- PSTV shows a decrease in Revenue. In the last year, the revenue decreased by -8.16%.
- Measured over the past years, PSTV shows a decrease in Revenue. The Revenue has been decreasing by -3.61% on average per year.
EPS 1Y (TTM)32.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.19%
Revenue 1Y (TTM)-8.16%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%-4.05%
3.2 Future
- PSTV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.88% yearly.
- PSTV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 89.59% yearly.
EPS Next Y88.56%
EPS Next 2Y38.61%
EPS Next 3Y25.07%
EPS Next 5Y15.88%
Revenue Next Year-1.68%
Revenue Next 2Y19.93%
Revenue Next 3Y62.94%
Revenue Next 5Y89.59%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. PSTV Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for PSTV. In the last year negative earnings were reported.
- Also next year PSTV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as PSTV's earnings are expected to grow with 25.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.61%
EPS Next 3Y25.07%
5. PSTV Dividend Analysis
5.1 Amount
- No dividends for PSTV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PSTV Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:PSTV (3/19/2026, 1:53:15 PM)
0.2393
+0 (+1.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners12.99%
Inst Owner Change96.71%
Ins Owners0.34%
Ins Owner Change61.52%
Market Cap44.10M
Revenue(TTM)5.26M
Net Income(TTM)-20.57M
Analysts81.82
Price Target6.02 (2415.67%)
Short Float %11.07%
Short Ratio1.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.85%
Min EPS beat(2)-96.08%
Max EPS beat(2)121.79%
EPS beat(4)2
Avg EPS beat(4)-166.61%
Min EPS beat(4)-695.44%
Max EPS beat(4)121.79%
EPS beat(8)5
Avg EPS beat(8)-72.35%
EPS beat(12)7
Avg EPS beat(12)-48.7%
EPS beat(16)10
Avg EPS beat(16)-30.19%
Revenue beat(2)0
Avg Revenue beat(2)-8.5%
Min Revenue beat(2)-8.69%
Max Revenue beat(2)-8.31%
Revenue beat(4)1
Avg Revenue beat(4)-2.38%
Min Revenue beat(4)-30.01%
Max Revenue beat(4)37.49%
Revenue beat(8)2
Avg Revenue beat(8)-2.75%
Revenue beat(12)3
Avg Revenue beat(12)-1.57%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.19%
PT rev (3m)-23.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-62.5%
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-35.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-32.21%
Revenue NY rev (1m)-8.35%
Revenue NY rev (3m)-27.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.73 | ||
| P/tB | 10.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.7
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.03
BVpS0.03
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -110.19% | ||
| ROE | -407.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.8% | ||
| Cap/Sales | 1.03% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | -38.18 |
F-Score4
WACC8.21%
ROIC/WACCN/A
Cap/Depr(3y)67.77%
Cap/Depr(5y)74.15%
Cap/Sales(3y)82.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.19%
EPS Next Y88.56%
EPS Next 2Y38.61%
EPS Next 3Y25.07%
EPS Next 5Y15.88%
Revenue 1Y (TTM)-8.16%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%-4.05%
Revenue Next Year-1.68%
Revenue Next 2Y19.93%
Revenue Next 3Y62.94%
Revenue Next 5Y89.59%
EBIT growth 1Y8.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.56%
OCF growth 3YN/A
OCF growth 5YN/A
PLUS THERAPEUTICS INC / PSTV Fundamental Analysis FAQ
What is the fundamental rating for PSTV stock?
ChartMill assigns a fundamental rating of 2 / 10 to PSTV.
What is the valuation status of PLUS THERAPEUTICS INC (PSTV) stock?
ChartMill assigns a valuation rating of 1 / 10 to PLUS THERAPEUTICS INC (PSTV). This can be considered as Overvalued.
How profitable is PLUS THERAPEUTICS INC (PSTV) stock?
PLUS THERAPEUTICS INC (PSTV) has a profitability rating of 0 / 10.
Can you provide the financial health for PSTV stock?
The financial health rating of PLUS THERAPEUTICS INC (PSTV) is 4 / 10.
What is the earnings growth outlook for PLUS THERAPEUTICS INC?
The Earnings per Share (EPS) of PLUS THERAPEUTICS INC (PSTV) is expected to grow by 88.56% in the next year.